Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-05

AUTHORS

Marc C. Chamberlain, Sandra K. Johnston

ABSTRACT

Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma. More... »

PAGES

427-432

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6

DOI

http://dx.doi.org/10.1007/s11060-010-0330-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019036958

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20680397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spinal Cord Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc C.", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance", 
          "id": "https://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnston", 
        "givenName": "Sandra K.", 
        "id": "sg:person.01122114252.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/cncr.23677", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003118803"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.3055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010751135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-006-9241-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015983460", 
          "https://doi.org/10.1007/s11060-006-9241-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(00)00690-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025413076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006470523052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027846301", 
          "https://doi.org/10.1023/a:1006470523052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.9027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029960724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.1515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034731213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0303-8467(96)00555-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041593830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1010680924975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043464068", 
          "https://doi.org/10.1023/a:1010680924975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2008.04.060", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048141455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052112015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1989.71.6.0842", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071095581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/jns.1998.88.2.0215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071098674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1227/01.neu.0000158318.66568.cc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077044204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078716995"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-05", 
    "datePublishedReg": "2011-05-01", 
    "description": "Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-010-0330-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "102"
      }
    ], 
    "name": "Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab", 
    "pagination": "427-432", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5ab466f50dd4a95ff7a22a02a00eb3d98196236a9db8e6230a41c89fd6aefd6e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20680397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-010-0330-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019036958"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-010-0330-6", 
      "https://app.dimensions.ai/details/publication/pub.1019036958"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-010-0330-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-010-0330-6'


 

This table displays all metadata directly associated to this object as RDF triples.

198 TRIPLES      21 PREDICATES      63 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-010-0330-6 schema:about N074b71c474b34207a95c612757fa2487
2 N1d936b891dc44fc5a2a241fbe95d6047
3 N28ab11f1b1094c718e677c6b9e18a5df
4 N2f231587ac3c4656a6f6933c241bf46a
5 N308db6cdc9364f23b27112c0195e657c
6 N4588a61ce0a94b03a0c18a574d67fb25
7 N5f7a2e67c46b43c3977b8e7e081c0e6b
8 N6399a97e2bab4a578f4f204d3f9e055c
9 N90d5106715b04814bb048bafc143a969
10 N9a5487a6e0e54061ba6621284b0f2f2f
11 Nb1f3d86eb7a6410780591ce22470fddb
12 Ncc6f9b59c70a4fbb92d8673c9ee1f843
13 Ncf0942bf32354d0ca432df0d7010bfcb
14 Ne0d961295e984dc3978fbe935eb7cb52
15 Nf8d1585d6cd1450eb071206aa154bf3c
16 Nfb979fed125b406a88cdd89ff5095c87
17 Nfcf485435ca240d6af2c7da46e23fa54
18 anzsrc-for:11
19 anzsrc-for:1109
20 schema:author N9c97fa1c7e224f2a83a4c39d5ea044ae
21 schema:citation sg:pub.10.1007/s11060-006-9241-y
22 sg:pub.10.1023/a:1006470523052
23 sg:pub.10.1023/a:1010680924975
24 https://doi.org/10.1002/cncr.23677
25 https://doi.org/10.1016/j.ijrobp.2008.04.060
26 https://doi.org/10.1016/s0303-8467(96)00555-0
27 https://doi.org/10.1016/s0360-3016(00)00690-8
28 https://doi.org/10.1056/nejmoa043330
29 https://doi.org/10.1200/jco.1990.8.7.1277
30 https://doi.org/10.1200/jco.2008.16.3055
31 https://doi.org/10.1200/jco.2008.19.8721
32 https://doi.org/10.1200/jco.2009.22.1515
33 https://doi.org/10.1200/jco.2009.26.3541
34 https://doi.org/10.1200/jco.2009.26.9027
35 https://doi.org/10.1227/01.neu.0000158318.66568.cc
36 https://doi.org/10.3171/jns.1989.71.6.0842
37 https://doi.org/10.3171/jns.1998.88.2.0215
38 schema:datePublished 2011-05
39 schema:datePublishedReg 2011-05-01
40 schema:description Primary spinal cord tumors constitute 2-4% of all primary central nervous system malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Six patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ratio and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after one cycle of therapy and thereafter following every two cycles of bevacizumab. Treatment-related complications included fatigue in six patients, constipation in 4, hypertension in 2, venous thrombosis in 2, and infection without neutropenia in 2. There were three grade 3 toxicities (1 each fatigue, leukopenia and venous thrombosis). There were no treatment-related deaths. After one cycle of bevacizumab, one patient (17%) demonstrated progressive disease, 2 (34%) partial responses and three (51%) stable disease. Overall median response or stable disease duration (disease free progression) was 7 months (range 3-11 months). Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N64841d1f544b447b8d03f41da2b87058
45 Nfc91af3617a14e748c640a0de69924ac
46 sg:journal.1094205
47 schema:name Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
48 schema:pagination 427-432
49 schema:productId N3e910786ac7a4d9e9ffc7d5311c76c6d
50 N688a8e8762e54d6a9787b7735e0fa868
51 N7acaa0d42dca41a5bc15de03f9853ef9
52 N99ba3a5d1fae4a9c924880adf4b3e080
53 N9d213fea3d2b4ae0afb2215038b731e4
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019036958
55 https://doi.org/10.1007/s11060-010-0330-6
56 schema:sdDatePublished 2019-04-11T00:20
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N1bfd71a9f80944ab8fae59fc3e290526
59 schema:url http://link.springer.com/10.1007%2Fs11060-010-0330-6
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N074b71c474b34207a95c612757fa2487 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Middle Aged
65 rdf:type schema:DefinedTerm
66 N1bfd71a9f80944ab8fae59fc3e290526 schema:name Springer Nature - SN SciGraph project
67 rdf:type schema:Organization
68 N1d936b891dc44fc5a2a241fbe95d6047 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Adult
70 rdf:type schema:DefinedTerm
71 N28ab11f1b1094c718e677c6b9e18a5df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Treatment Outcome
73 rdf:type schema:DefinedTerm
74 N2f231587ac3c4656a6f6933c241bf46a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Glioblastoma
76 rdf:type schema:DefinedTerm
77 N308db6cdc9364f23b27112c0195e657c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N3e910786ac7a4d9e9ffc7d5311c76c6d schema:name nlm_unique_id
81 schema:value 8309335
82 rdf:type schema:PropertyValue
83 N4588a61ce0a94b03a0c18a574d67fb25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Spinal Cord Neoplasms
85 rdf:type schema:DefinedTerm
86 N508bf9c96b6c436eb07781cc240399e7 rdf:first sg:person.01122114252.85
87 rdf:rest rdf:nil
88 N5f7a2e67c46b43c3977b8e7e081c0e6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Young Adult
90 rdf:type schema:DefinedTerm
91 N6399a97e2bab4a578f4f204d3f9e055c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Salvage Therapy
93 rdf:type schema:DefinedTerm
94 N64841d1f544b447b8d03f41da2b87058 schema:issueNumber 3
95 rdf:type schema:PublicationIssue
96 N688a8e8762e54d6a9787b7735e0fa868 schema:name pubmed_id
97 schema:value 20680397
98 rdf:type schema:PropertyValue
99 N7acaa0d42dca41a5bc15de03f9853ef9 schema:name dimensions_id
100 schema:value pub.1019036958
101 rdf:type schema:PropertyValue
102 N90d5106715b04814bb048bafc143a969 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 N99ba3a5d1fae4a9c924880adf4b3e080 schema:name readcube_id
106 schema:value 5ab466f50dd4a95ff7a22a02a00eb3d98196236a9db8e6230a41c89fd6aefd6e
107 rdf:type schema:PropertyValue
108 N9a5487a6e0e54061ba6621284b0f2f2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Antibodies, Monoclonal
110 rdf:type schema:DefinedTerm
111 N9c97fa1c7e224f2a83a4c39d5ea044ae rdf:first sg:person.01326261166.36
112 rdf:rest N508bf9c96b6c436eb07781cc240399e7
113 N9d213fea3d2b4ae0afb2215038b731e4 schema:name doi
114 schema:value 10.1007/s11060-010-0330-6
115 rdf:type schema:PropertyValue
116 Nb1f3d86eb7a6410780591ce22470fddb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Neoplasm Recurrence, Local
118 rdf:type schema:DefinedTerm
119 Ncc6f9b59c70a4fbb92d8673c9ee1f843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Magnetic Resonance Imaging
121 rdf:type schema:DefinedTerm
122 Ncf0942bf32354d0ca432df0d7010bfcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Bevacizumab
124 rdf:type schema:DefinedTerm
125 Ne0d961295e984dc3978fbe935eb7cb52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Angiogenesis Inhibitors
127 rdf:type schema:DefinedTerm
128 Nf8d1585d6cd1450eb071206aa154bf3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Female
130 rdf:type schema:DefinedTerm
131 Nfb979fed125b406a88cdd89ff5095c87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Retrospective Studies
133 rdf:type schema:DefinedTerm
134 Nfc91af3617a14e748c640a0de69924ac schema:volumeNumber 102
135 rdf:type schema:PublicationVolume
136 Nfcf485435ca240d6af2c7da46e23fa54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antibodies, Monoclonal, Humanized
138 rdf:type schema:DefinedTerm
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
143 schema:name Neurosciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1094205 schema:issn 0167-594X
146 1573-7373
147 schema:name Journal of Neuro-Oncology
148 rdf:type schema:Periodical
149 sg:person.01122114252.85 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
150 schema:familyName Johnston
151 schema:givenName Sandra K.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122114252.85
153 rdf:type schema:Person
154 sg:person.01326261166.36 schema:affiliation https://www.grid.ac/institutes/grid.430269.a
155 schema:familyName Chamberlain
156 schema:givenName Marc C.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
158 rdf:type schema:Person
159 sg:pub.10.1007/s11060-006-9241-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015983460
160 https://doi.org/10.1007/s11060-006-9241-y
161 rdf:type schema:CreativeWork
162 sg:pub.10.1023/a:1006470523052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027846301
163 https://doi.org/10.1023/a:1006470523052
164 rdf:type schema:CreativeWork
165 sg:pub.10.1023/a:1010680924975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043464068
166 https://doi.org/10.1023/a:1010680924975
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1002/cncr.23677 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003118803
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.ijrobp.2008.04.060 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048141455
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0303-8467(96)00555-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041593830
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0360-3016(00)00690-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025413076
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1200/jco.2009.22.1515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034731213
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1200/jco.2009.26.9027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029960724
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1227/01.neu.0000158318.66568.cc schema:sameAs https://app.dimensions.ai/details/publication/pub.1077044204
191 rdf:type schema:CreativeWork
192 https://doi.org/10.3171/jns.1989.71.6.0842 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071095581
193 rdf:type schema:CreativeWork
194 https://doi.org/10.3171/jns.1998.88.2.0215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071098674
195 rdf:type schema:CreativeWork
196 https://www.grid.ac/institutes/grid.430269.a schema:alternateName Seattle Cancer Care Alliance
197 schema:name Departments of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, 98109-1023, Seattle, WA, USA
198 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...